

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
18 April 2019 (18.04.2019)



(10) International Publication Number
WO 2019/075395 A1

(51) International Patent Classification:

C07K 16/28 (2006.01) C07K 14/55 (2006.01)
C07K 14/54 (2006.01)

(21) International Application Number:

PCT/US2018/055705

(22) International Filing Date:

12 October 2018 (12.10.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/571,608 12 October 2017 (12.10.2017) US
62/628,973 10 February 2018 (10.02.2018) US

(71) Applicant: **ICELL GENE THERAPEUTICS, LLC**
[US/US]; 25 Health Sciences Drive, Stony Brook, NY
11790 (US).

(72) Inventors: **MA, Yupo**; Icell Gene Therapeutics, LLC, 25
Health Sciences Drive, Stony Brook, NY 11790 (US). **PINZ, Kevin**; Icell Gene Therapeutics, LLC, 25 Health
Sciences Drive, Stony Brook, NY 11790 (US). **JIANG, Xun**; Icell Gene Therapeutics, LLC, 25 Health Sciences
Drive, Stony Brook, NY 11790 (US). **WADA, Masayuki**;
Icell Gene Therapeutics, LLC, 25 Health Sciences Drive,
Stony Brook, NY 11790 (US). **CHEN, Kevin**; Icell Gene
Therapeutics, LLC, 25 Health Sciences Drive, Stony Brook,
NY 11790 (US).

(74) Agent: **WOO, Perry, Y.** et al.; Hoffmann & Baron, LLP,
6900 Jericho Turnpike, Syosset, NY 11791 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: COMPOUND CHIMERIC ANTIGEN RECEPTOR (CCAR) TARGETING MULTIPLE ANTIGENS, COMPOSITIONS
AND METHODS OF USE THEREOF

CD269-CD319 (BC1cCAR) lentiviral schematic




Figure 1A

(57) Abstract: In one embodiment, the present disclosure provides an engineered cell having a first chimeric antigen receptor polypeptide including a first antigen recognition domain, a first signal peptide, a first hinge region, a first transmembrane domain, a first co-stimulatory domain, and a first signaling domain; and a second chimeric antigen receptor polypeptide including a second antigen recognition domain, a second signal peptide, a second hinge region, a second transmembrane domain, a second co-stimulatory domain, and a second signaling domain; wherein the first antigen recognition domain is different than the second antigen recognition domain.

WO 2019/075395 A1